Showing results (171-180 of 292) with videos related to
Sort By:
Pageof 30
The Journal of Antimicrobial Chemotherapy|April 10, 2008
Opposing expectations and suboptimal use of a local antibiotic hospital guideline: a qualitative studyPieter-Jan Cortoos, Karel De Witte, Willy E Peetermans, et al.Frontiers in Public Health|February 18, 2025
Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variantSophie Marbaix, Steven Simoens, Philippe Clevenbergh, et al.Journal of Market Access & Health Policy|April 24, 2026
When Do Annuity-Based Payments Help to Address the Affordability Challenge of Funding Advanced Therapies? Insights from a Budget Impact SimulationWalter Van Dyck, Sissel Michelsen, David Veredas, et al.Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable PracticesLiese Barbier, Steven Simoens, Caroline Soontjens, et al.Diabetes, Obesity & Metabolism|September 1, 2025
Barriers to adoption of biosimilar insulins in Europe: A mixed-methods studyElif Car, Garm Habets, Arnold G Vulto, et al.The International Journal of Pharmacy Practice|March 11, 2010
Cardiovascular drug use prior to diagnosis of diabetes: a pilot study in community pharmacySteven Simoens, Sandra De Coster, Marleen Dethier, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 5, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient SettingEvelien Moorkens, Steven Simoens, Per Troein, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 5, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital SettingEvelien Moorkens, Steven Simoens, Per Troein, et al.Frontiers in Medicine|March 26, 2021
Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in HemophiliaEline van Overbeeke, Brett Hauber, Sissel Michelsen, et al.British Journal of Cancer|July 2, 2019
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilarsLiese Barbier, Paul Declerck, Steven Simoens, et al.Pageof 30